24 February 2021 in Journal of Pediatric Gastroenterology and Nutrition
VCVibeke Brix Christensen
+2
26 September 2024 in Journal of Autoimmunity
Adult-onset immune-mediated inflammatory disease (IMID) increases the risk of several cancers. However, data on pediatric-onset IMID (pIMID) remains scarce. We estimated the long-term cancer risk in pIMID and the association between medical treatment and specific cancers. We used the nationwide Danish health registers to identify pIMID patients diagnosed from Jan 1, 1980 to Dec 31, 2018. Patients were matched with ten reference individuals based on age, sex, and residence. The primary exposure was pIMID, including autoimmune hepatitis, primary sclerosing cholangitis, Crohn's disease, ulcerative colitis, juvenile idiopathic arthritis, systemic lupus erythematosus, vasculitis, and connective tissue disease. Secondary exposures were immunomodulators and tumor necrosis factor-α antagonists (anti-TNFα). The primary outcome was cancer. Estimates are presented as hazard ratios adjusted for family income at diagnosis (AHR). We included 12,664 pIMID patients and 109,274 reference individuals. Median follow-up time was 10.6 (interquartile range: 5.4-17.7) years for patients and 10.2 (interquartile range: 5.2-17.3) years for reference individuals. Patients with pIMID had a twofold higher cancer risk (AHR 2.2 [95 % confidence interval (CI): 1.8-2.6]) compared with reference individuals. Thiopurine treatment was associated with a higher risk of lymphoma (AHR 6.1 [95%CI: 2.2-16.8]) and skin cancer (AHR 6.1 [95%CI: 2.4-15.4]). Anti-TNFα treatment was associated with a higher risk of lymphoma (AHR 4.9 [95%CI: 1.1-22.6]). We found an increased cancer risk in patients with pIMID followed into adulthood. Additionally, thiopurines and anti-TNFα were associated with increased lymphoma and skin cancer risks. This highlights the importance of individualized immunotherapy and cancer surveillance.
24 February 2023 in Journal of Hepatology
28 May 2025 in Liver International
Background and Aims: Since described in 2015, NBAS‐associated disease has emerged as an important cause of acute liver failure (ALF) in children. We analysed the variable expression, genotype–phenotype association, outcome and prognostic factors of the hepatic involvement. Methods: Individuals with biallelic pathogenic NBAS variants were recruited within an international observational study, including new and previously published patients. Results: We studied 230 individuals, including 13 previously unreported patients. The liver was the most frequently affected organ (63.4%), with 41.3% experiencing at least one ALF. The median age at onset was 0.9 years, the median age at last ALF 5 years, the latest ALF occurred at 24 years. Liver crises were triggered by febrile infections and presented with highly increased hepatic transaminases. Liver involvement varied significantly between the subgroups: 91.7% of patients with infantile liver failure syndrome type 2 and 88.9% of patients from the combined subgroup (variants affecting β‐propeller domain) presented with ALF, whereas SOPH (stature, optic atrophy, Pelger–Huët anomaly) patients mostly had either no liver involvement (66.4%) or persistently elevated transaminases without ALF (28%). The rate of native liver survival was 83.9%; 16 individuals underwent liver transplantation and 24 died. Conclusion: Liver abnormalities are common and the leading cause of death in NBAS‐associated disease. There is a clear genotype–phenotype association regarding the hepatic involvement. Liver crises occur primarily during infancy; however, early medical attention in case of febrile infections is necessary at all ages. Liver transplantation prevents ALF, but its risks must be weighed against the frequency and severity of liver crises decreasing with age.
8 May 2025 in The Journal of Pediatrics
To compare the remission rates after 1 year of treatment between two regimens: tacrolimus (with or without prednisolone) or prednisolone (with or without azathioprine) in children with autoimmune liver disease. Retrospective data from children (n = 157) with biopsy-proven autoimmune liver disease in five tertiary northern European centers were included. Data were collected at presentation and after 3, 6, and 12 months. Initially, 111 were treated with prednisolone (with or without azathioprine) and 46 received tacrolimus (with or without prednisolone) (median start dose prednisolone: 0.99 mg/kg and 0.43 mg/kg, respectively). At diagnosis, alanine transaminase levels were similar, but the rate of advanced fibrosis was significantly higher in the tacrolimus (with or without prednisolone) group. Lower rates of alanine transaminase normalization in the tacrolimus (with or without prednisolone) group were found at 3 months (26.8 vs 58.0%, P < .001) and 6 months (46.2% vs 68.8, P = .014), but not at 1 year (68.2 vs 76.2%, P > .05). The same pattern was seen for immunoglobulin G. Despite slower treatment response for patients initially started on tacrolimus (with or without prednisolone) at 3 and 6 months, biochemical and immunological responses to the two different regimens appeared equivalent at 1 year after treatment initiation.
6 June 2022 in Pediatric Transplantation
VMVibeke Schaffalitzky de Muckadell
Vibeke Schaffalitzky de Muckadell
Background: Long‐time survivors of pediatric liver transplantation have an increased incidence of the metabolic syndrome. Adult recipients have an increased risk of post‐transplantation obesity; however, pediatric data are limited.Methods: The study included 42 recipients of pediatric liver transplantation in Denmark, transplanted between 1990 and 2014. The study participants were examined with anthropometric measures, dual‐energy X‐ray scans and blood samples. From the anthropometric measures, body mass index (BMI) and BMI standard deviation score (SDS) were calculated. From the dual‐energy X‐ray scans, fat percent was assessed, and body fat mass index (BFMI) was calculated.Results: The median age was 17.4 years (range 4.1–38.9) at the time of the study, and the median time since transplantation was 8.5 years (range 0.4–23.9). The prevalence of overweight and obesity was 31.0% based on BMI SDS (age below 18) and BMI (age 18 and above). When compared to the participants with normal weight, the participants with overweight and obesity had a higher BFMI (9.29 vs 5.57 kg/m2, p < .001) and fat percent (38.35% vs 29.50%, p = .006). They had higher levels of total cholesterol (4.3 vs 3.6 mmol/L, p = .023) and low‐density lipoprotein (2.5 vs 1.7, p = .015), and had had longer time since transplantation (15.6 vs 8.5 years respectively, p = .045).Conclusions: Long‐time survivors of pediatric liver transplantation have a higher BMI or BMI SDS than the general pediatric population. The obesity is characterized by a higher BFMI, fat percent, and cholesterols levels, when compared to recipients without overweight or obesity.